In 2020, I took part in a psilocybin trial. Psilocybin is the psychedelic ingredient found in magic mushrooms. The trial was carried out at a London hospital and designed to study the potential benefits of psilocybin for treatment-resistant depression — a condition I have struggled with for 55 years.
The program consisted of five therapy sessions, a single dosing day, then six weeks of integration therapy where I discussed, with the therapist, my psilocybin experience.
The research team running the study were young, forward-thinking psychiatrists, neuroscientists, and therapists — all of whom were into meditation, holotropic breathwork, and the ideas of Carl Jung.